Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has grant...
Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23) Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results...
Burry buys puts on ARKK, possibly as a hedge to Alphabet and Facebook positions. He also took a position in Discovery, which is merging with AT&T's entertainment assets and will collapse its multiple share class structure when the deal closes. Michael Burry takes his first rep...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Marinus Pharmaceuticals, Inc. (MRNS) Q2 2021 Results Conference Call August 10, 2021 8:30 AM ET Company Participants Scott Braunstein – Chief Executive Officer Sasha Damouni – Vice President, Investor Relations and Corporate Communications Joe Hulihan – Chief Medical Offi...
Anticipate initiating a Phase 3 trial of adjunctive ganaxolone in tuberous sclerosis complex (TSC) in Q3 2021, targeting first patient enrolled during Q4 2021; continue to expect topline Phase 2, open label data in Q3 2021 European Medicines Agency (EMA) is expected to accept acce...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the second quarter ended June 30, 2021 before the market opens on Au...
Marinus Pharmaceuticals (NASDAQ:MRNS) perks up 6% premarket after submitting a New Drug Application (NDA) to the FDA for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy. FDA notification le...
Orion obtains rights to commercialize both the oral and IV franchises of ganaxolone in Europe Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion’s expertise in rare orphan diseases, antiepilepti...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...